Literature DB >> 31899272

Photodynamic cancer therapy enhances accumulation of nanoparticles in tumor-associated myeloid cells.

Ruben V Huis In 't Veld1, Laila Ritsma2, Jan Willem Kleinovink3, Ivo Que1, Ferry Ossendorp4, Luis J Cruz5.   

Abstract

In cancer treatment, nanomedicines may be employed in an attempt to improve the tumor localization of antineoplastic drugs e.g. immunotherapeutic agents either through passive or active targeting, thereby potentially enhancing therapeutic effect and reducing undesired off-target effects. However, a large number of administrated nanocarriers often fail to reach the tumor area. In the present study, we show that photodynamic therapy (PDT) enhances the tumor accumulation of systemically administered lipid-PEG layer coated poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NP). Intravital microscopy and histological analysis of the tumor area reveal that the tumor vasculature was disrupted after PDT, disturbing blood flow and coinciding with entrapment of nanocarriers in the tumor area. We observed that the nanoparticles accumulating after treatment do not confine to specific locations within the tumor, but rather localize to various cells present throughout the tumor area. Finally, we show by flow cytometry that NP accumulation occurred mostly in immune cells of the myeloid lineage present in the tumor microenvironment (TME) as well as in tumor cells, albeit to a lower extent. These data expose opportunities for combination treatments of clinical PDT with NP-based immunotherapy to modulate the TME and improve antitumor immune responses.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Delivery; Immune modulation; Immunotherapy; Nanoparticles; PLGA; Pharmacology; Photodynamic therapy; Theranostics; Tumor microenvironment

Mesh:

Substances:

Year:  2019        PMID: 31899272     DOI: 10.1016/j.jconrel.2019.12.052

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  7 in total

1.  M1-derived extracellular vesicles enhance photodynamic therapy and promote immunological memory in preclinical models of colon cancer.

Authors:  Ruben V Huis In 't Veld; Pablo Lara; Martine J Jager; Roman I Koning; Ferry Ossendorp; Luis J Cruz
Journal:  J Nanobiotechnology       Date:  2022-06-03       Impact factor: 9.429

2.  Photodynamic Therapy in Combination with the Hepatitis B Core Virus-like Particles (HBc VLPs) to Prime Anticancer Immunity for Colorectal Cancer Treatment.

Authors:  Yang Hao; Zili Gu; Zhenfeng Yu; Timo Schomann; Sana Sayedipour; Julio C Aguilar; Peter Ten Dijke; Luis J Cruz
Journal:  Cancers (Basel)       Date:  2022-05-31       Impact factor: 6.575

Review 3.  Pathological and Pharmacological Roles of Mitochondrial Reactive Oxygen Species in Malignant Neoplasms: Therapies Involving Chemical Compounds, Natural Products, and Photosensitizers.

Authors:  Yasuyoshi Miyata; Yuta Mukae; Junki Harada; Tsuyoshi Matsuda; Kensuke Mitsunari; Tomohiro Matsuo; Kojiro Ohba; Hideki Sakai
Journal:  Molecules       Date:  2020-11-11       Impact factor: 4.411

Review 4.  Current Clinical and Pre-Clinical Imaging Approaches to Study the Cancer-Associated Immune System.

Authors:  Christopher G Mueller; Christian Gaiddon; Aïna Venkatasamy
Journal:  Front Immunol       Date:  2021-09-03       Impact factor: 7.561

Review 5.  Nanoparticle delivery in vivo: A fresh look from intravital imaging.

Authors:  Qiaoya Lin; Parinaz Fathi; Xiaoyuan Chen
Journal:  EBioMedicine       Date:  2020-08-25       Impact factor: 8.143

Review 6.  Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy.

Authors:  Yang Hao; Chih Kit Chung; Zhenfeng Yu; Ruben V Huis In 't Veld; Ferry A Ossendorp; Peter Ten Dijke; Luis J Cruz
Journal:  Pharmaceutics       Date:  2022-01-04       Impact factor: 6.321

Review 7.  Surface-functionalised hybrid nanoparticles for targeted treatment of cancer.

Authors:  Hasnat Tariq; Syed Ali Imran Bokhari
Journal:  IET Nanobiotechnol       Date:  2020-09       Impact factor: 1.847

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.